{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:20:45Z","timestamp":1791073245580,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The therapeutic landscape of multiple sclerosis (MS) is rapidly evolving, with increasing emphasis on early initiation of high-efficacy disease-modifying therapies (heDMTs). However, real-world data on predictors of first-line heDMT use and its outcomes remain scarce in the Middle East.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify demographic and clinical factors influencing the choice of first-line heDMT vs. platform therapy in relapsing-remitting MS (RRMS) and to evaluate whether initial treatment class impacts disability outcomes and treatment persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 826 RRMS patients treated at a tertiary center in Saudi Arabia between 2016 and 2024. Predictors of initiating heDMT were identified using multivariable logistic regression. Disability status (EDSS category) was analyzed using ordinal logistic regression. Treatment persistence and causes of discontinuation were examined using Kaplan\u2013Meier survival analysis, Cox proportional hazards modeling, and Fine\u2013Gray competing-risks regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 826 patients, 330 (40%) received heDMTs as first-line therapy. Initiation in the later treatment era (2019\u20132024) strongly predicted heDMT use compared with the early treatment era (2008\u20132013; OR = 48.8;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001), as did cerebellar symptom onset (OR = 2.51;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.025). Age, sex, and comorbidities were not significant predictors. Starting on a heDMT did not translate into higher or lower disability levels compared with platform therapies (OR = 1.08;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.767). However, patients initiating heDMTs demonstrated superior treatment persistence (12-month persistence: 91.7 vs. 83.4%;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001) and a markedly lower risk of discontinuation (HR = 0.41;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Competing-risks analysis showed that heDMT users were significantly less likely to discontinue due to inefficacy or adverse events, but more likely to stop for other reasons, such as pregnancy, preference, or supply issues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>First-line use of heDMTs in Saudi Arabia has increased substantially over recent years, particularly among patients with cerebellar onset. While disability outcomes were similar between treatment groups, initiating heDMTs conferred clear advantages in persistence and tolerability. These findings reinforce the paradigm shift toward early intensive MS management and highlight the need for broader access and guideline-driven implementation of heDMTs in the region.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1738815","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:26:27Z","timestamp":1769750787000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Khalid","family":"Bin Aziz","sequence":"first","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer S.","family":"Alhowaish","sequence":"additional","affiliation":[{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Neurology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feras","family":"Alanazi","sequence":"additional","affiliation":[{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Neurology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mezyed","family":"Alghanim","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Alkhreigi","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Almubarak","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Aleisa","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouf","family":"AlTuwaijri","sequence":"additional","affiliation":[{"name":"College of Medicine, Princess Norah University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad","family":"Alanazi","sequence":"additional","affiliation":[{"name":"College of Medicine, Northern Border University","place":["Arar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Al Malik","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Neurology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17562864241284372","DOI":"10.1177\/17562864241284372","article-title":"Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management","volume":"17","author":"Oreja-Guevara","year":"2024","journal-title":"Ther Adv Neurol Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12883-020-1629-3","article-title":"Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study","volume":"20","author":"AlJumah","year":"2020","journal-title":"BMC Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/jpm12010119","article-title":"Escalation vs. early intense therapy in multiple sclerosis","volume":"12","author":"Casanova","year":"2022","journal-title":"J Pers Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr Treat Options Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"104581","DOI":"10.1016\/j.msard.2023.104581","article-title":"Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: a systematic review and meta-analysis","volume":"71","author":"Pipek","year":"2023","journal-title":"Mult Scler Relat Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1007\/s00415-024-12305-4","article-title":"Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption","volume":"271","author":"Singer","year":"2024","journal-title":"J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s40120-022-00401-4","article-title":"Unmet needs and treatment of relapsing-remitting multiple sclerosis in Saudi Arabia: focus on the role of ofatumumab","volume":"11","author":"Craner","year":"2022","journal-title":"Neurol Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"105896","DOI":"10.1016\/j.msard.2024.105896","article-title":"Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis","volume":"91","author":"Li","year":"2024","journal-title":"Mult Scler Relat Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"693017","DOI":"10.3389\/fneur.2021.693017","article-title":"Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry","volume":"12","author":"Simonsen","year":"2021","journal-title":"Front Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1001\/jamaneurol.2023.2125","article-title":"Initiation patterns of disease-modifying therapies for multiple sclerosis among US adults and children, 2001\u20132020","volume":"80","author":"Henderson","year":"2023","journal-title":"JAMA Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"105888","DOI":"10.1016\/j.msard.2024.105888","article-title":"Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis","volume":"91","author":"Hersh","year":"2024","journal-title":"Mult Scler Relat Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"106702","DOI":"10.1016\/j.msard.2025.106702","article-title":"Effect of early highly effective treatment compared to an escalating treatment strategy in multiple sclerosis","volume":"103","author":"Norborg","year":"2025","journal-title":"Mult Scler Relat Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/acn3.70130","article-title":"Real-world comparison of high-efficacy versus non-high-efficacy therapies in multiple sclerosis","volume":"12","author":"Al-Araji","year":"2025","journal-title":"Ann Clin Transl Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e16289","DOI":"10.1111\/ene.16289","article-title":"Real-world persistence of multiple sclerosis disease-modifying therapies","volume":"31","author":"Tallantyre","year":"2024","journal-title":"Eur J Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"106690","DOI":"10.1016\/j.msard.2025.106690","article-title":"Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: a real-life observational study","volume":"104","author":"Didierjean","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s40120-024-00650-5","article-title":"Practical recommendations from the gulf region on the therapeutic use of cladribine tablets for the management of relapsing multiple sclerosis: impact of the latest real-world evidence on clinical practice","volume":"13","author":"Yamout","year":"2024","journal-title":"Neurol Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12883-023-03184-9","article-title":"Exploring physicians' prescribing behavior in Saudi Arabia","volume":"23","author":"Al-Omar","year":"2023","journal-title":"BMC Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"106124","DOI":"10.1016\/j.msard.2024.106124","article-title":"Real-life impact of fingolimod in Saudi patients","volume":"92","author":"Aljahdali","year":"2024","journal-title":"Mult Scler Relat Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40120-024-00707-5","article-title":"Administration and monitoring burden of high-efficacy DMTs for MS","volume":"14","author":"Saudi","year":"2025","journal-title":"Neurol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/pn-2022-003426","article-title":"Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines","volume":"23","author":"Dobson","year":"2023","journal-title":"Pract Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"103061","DOI":"10.1016\/j.jogoh.2025.103061","article-title":"Multiple sclerosis, fertility, pregnancy, and assisted reproductive technology: current knowledge","volume":"55","author":"Trabaud","year":"2025","journal-title":"J Gynecol Obstet Hum Reprod."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40263-022-00961-x","article-title":"The efficacy and safety of anti-CD20 antibody treatments in relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"36","author":"Wu","year":"2022","journal-title":"CNS Drugs."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1738815\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:26:28Z","timestamp":1769750788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1738815\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":24,"alternative-id":["10.3389\/fneur.2026.1738815"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1738815","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"1738815"}}